Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 2 | 2021 | 206 | 0.770 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 0.730 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 629 | 0.620 |
Why?
|
| Glutathione | 4 | 2011 | 343 | 0.570 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 561 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2015 | 87 | 0.230 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2021 | 14 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 266 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 30 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
| Protein Disulfide-Isomerases | 2 | 2011 | 27 | 0.180 |
Why?
|
| PPAR delta | 1 | 2019 | 14 | 0.170 |
Why?
|
| Dietary Fats | 1 | 2019 | 103 | 0.160 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2018 | 268 | 0.160 |
Why?
|
| Dinoprostone | 1 | 2019 | 110 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 446 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 306 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 199 | 0.160 |
Why?
|
| Dental Pulp | 1 | 2018 | 10 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.160 |
Why?
|
| Periodontal Ligament | 1 | 2018 | 16 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2020 | 215 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 231 | 0.150 |
Why?
|
| bcl-X Protein | 1 | 2017 | 36 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 331 | 0.150 |
Why?
|
| Osteoblasts | 1 | 2018 | 99 | 0.150 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 64 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 332 | 0.140 |
Why?
|
| Neoplasms | 3 | 2015 | 1667 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2018 | 152 | 0.140 |
Why?
|
| Circadian Rhythm | 2 | 2008 | 218 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2014 | 2689 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2019 | 447 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 118 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 135 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2014 | 11 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 468 | 0.120 |
Why?
|
| Animals | 10 | 2021 | 20881 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 33 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1034 | 0.110 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 63 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 213 | 0.110 |
Why?
|
| Mice | 8 | 2021 | 8474 | 0.110 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 1851 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 304 | 0.100 |
Why?
|
| Humans | 14 | 2021 | 68618 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2011 | 284 | 0.100 |
Why?
|
| Reactive Nitrogen Species | 1 | 2011 | 32 | 0.090 |
Why?
|
| Glutathione Transferase | 1 | 2011 | 166 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2015 | 902 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 2791 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 142 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2011 | 215 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 756 | 0.080 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2008 | 2 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1173 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 499 | 0.080 |
Why?
|
| beta Catenin | 1 | 2008 | 73 | 0.080 |
Why?
|
| Aged | 2 | 2021 | 14862 | 0.070 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 219 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2008 | 237 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2009 | 382 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 271 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 230 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2019 | 682 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2017 | 294 | 0.070 |
Why?
|
| Male | 4 | 2021 | 37321 | 0.070 |
Why?
|
| Middle Aged | 2 | 2021 | 21147 | 0.060 |
Why?
|
| Cyclin E | 1 | 2005 | 19 | 0.060 |
Why?
|
| Female | 5 | 2021 | 38074 | 0.060 |
Why?
|
| HCT116 Cells | 2 | 2019 | 63 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2005 | 44 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2008 | 753 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 331 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 434 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2021 | 42 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 37 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 196 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1174 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2021 | 326 | 0.040 |
Why?
|
| Cysteine | 2 | 2011 | 112 | 0.040 |
Why?
|
| Cyclooxygenase 1 | 1 | 2019 | 29 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 714 | 0.040 |
Why?
|
| Nanog Homeobox Protein | 1 | 2019 | 6 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2018 | 2673 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2019 | 38 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2019 | 166 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 800 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2019 | 160 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 138 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 81 | 0.040 |
Why?
|
| Thiazoles | 1 | 2019 | 95 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 54 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 84 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 852 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 200 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2017 | 52 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 615 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 260 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2017 | 141 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 170 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 247 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 442 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 1033 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 254 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2015 | 54 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 282 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Thiazolidines | 1 | 2014 | 23 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 489 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 782 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 507 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 237 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 181 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 710 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 184 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 266 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 369 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1174 | 0.030 |
Why?
|
| Cell Movement | 1 | 2014 | 630 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1027 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1200 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 50 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 317 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1692 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2009 | 50 | 0.020 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2009 | 30 | 0.020 |
Why?
|
| para-Aminobenzoates | 1 | 2009 | 27 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7029 | 0.020 |
Why?
|
| Azo Compounds | 1 | 2009 | 33 | 0.020 |
Why?
|
| Protein Folding | 1 | 2009 | 82 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2009 | 99 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 567 | 0.020 |
Why?
|
| CLOCK Proteins | 1 | 2008 | 7 | 0.020 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2008 | 26 | 0.020 |
Why?
|
| Period Circadian Proteins | 1 | 2008 | 16 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 90 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 420 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 306 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 267 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2550 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 546 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 1083 | 0.020 |
Why?
|
| Proteomics | 1 | 2009 | 246 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.020 |
Why?
|
| Proteins | 1 | 2011 | 474 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 1447 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2011 | 718 | 0.020 |
Why?
|
| Photoperiod | 1 | 2005 | 11 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2005 | 14 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 621 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2005 | 114 | 0.010 |
Why?
|
| Locomotion | 1 | 2005 | 135 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 597 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|